• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Could direct oral anticoagulants be an alternative to vitamin K antagonists in patients with hypertrophic cardiomyopathy and atrial fibrillation?

作者信息

Li Biao, Sun Chao, Qin Fen, Liu Na, Wu Zhihong, Liu Qiming

机构信息

Department of Cardiology/Cardiac Catheterisation Lab, Second Xiangya Hospital, Central South University, Changsha City, Hunan Province 410011, China.

Department of Cardiology/Cardiac Catheterisation Lab, Second Xiangya Hospital, Central South University, Changsha City, Hunan Province 410011, China.

出版信息

Int J Cardiol. 2018 Apr 1;256:39. doi: 10.1016/j.ijcard.2017.10.113.

DOI:10.1016/j.ijcard.2017.10.113
PMID:29454418
Abstract
摘要

相似文献

1
Could direct oral anticoagulants be an alternative to vitamin K antagonists in patients with hypertrophic cardiomyopathy and atrial fibrillation?对于肥厚型心肌病合并心房颤动的患者，直接口服抗凝剂能否替代维生素K拮抗剂？
Int J Cardiol. 2018 Apr 1;256:39. doi: 10.1016/j.ijcard.2017.10.113.
2
Vitamin K antagonist use for all patients with hypertrophic cardiomyopathy and atrial fibrillation: analysis of the literature and guideline review.所有肥厚型心肌病合并心房颤动患者使用维生素K拮抗剂：文献分析与指南回顾
Future Cardiol. 2014 Mar;10(2):229-33. doi: 10.2217/fca.13.109.
3
Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.非维生素 K 拮抗剂口服抗凝剂与华法林在 III 期心房颤动试验中的净临床获益。
Am J Med. 2015 Sep;128(9):1007-14.e2. doi: 10.1016/j.amjmed.2015.03.034. Epub 2015 Apr 22.
4
Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.心房颤动卒中后抗凝治疗的三个月风险效益概况：SAMURAI-非瓣膜性心房颤动（NVAF）研究
Int J Stroke. 2016 Jul;11(5):565-74. doi: 10.1177/1747493016632239. Epub 2016 Feb 29.
5
Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants.老年合并症心房颤动患者的卒中预防：聚焦于非维生素K拮抗剂口服抗凝药。
Clin Interv Aging. 2015 Sep 3;10:1431-44. doi: 10.2147/CIA.S80641. eCollection 2015.
6
Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.非维生素K拮抗剂口服抗凝剂用于非瓣膜性心房颤动患者的疗效和安全性比较
Semin Thromb Hemost. 2015 Mar;41(2):146-53. doi: 10.1055/s-0035-1544156. Epub 2015 Feb 15.
7
Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation.非瓣膜性心房颤动患者的直接口服抗凝剂与心血管预防
Expert Opin Pharmacother. 2017 Jan;18(1):67-77. doi: 10.1080/14656566.2016.1267140. Epub 2016 Dec 15.
8
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.新型口服抗凝药物在房颤卒中预防中的应用：重点关注阿哌沙班。
Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7.
9
Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation.直接口服抗凝剂在肥厚型心肌病合并心房颤动患者中的应用。
Int J Cardiol. 2017 Dec 1;248:232-238. doi: 10.1016/j.ijcard.2017.08.010. Epub 2017 Aug 7.
10
Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.心房颤动的卒中预防：新型口服抗凝剂的影响。
Clin Appl Thromb Hemost. 2013 Jun;19(3):241-8. doi: 10.1177/1076029612458148. Epub 2012 Sep 4.